Quince Therapeutics, Inc.
QNCX
$1.22
-$0.04-3.18%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 3.64M | 3.28M | 3.34M | 4.79M | 4.28M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.24M | 11.36M | 9.90M | 12.93M | 10.11M |
| Operating Income | -16.24M | -11.36M | -9.90M | -12.93M | -10.11M |
| Income Before Tax | -36.31M | -13.49M | -15.98M | -14.98M | -12.45M |
| Income Tax Expenses | 3.15M | -46.00K | 67.00K | 47.00K | 7.00K |
| Earnings from Continuing Operations | -39.46M | -13.44M | -16.05M | -15.03M | -12.46M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -39.46M | -13.44M | -16.05M | -15.03M | -12.46M |
| EBIT | -16.24M | -11.36M | -9.90M | -12.93M | -10.11M |
| EBITDA | -16.20M | -11.33M | -9.86M | -12.90M | -10.09M |
| EPS Basic | -7.09 | -2.49 | -3.44 | -3.42 | -2.85 |
| Normalized Basic EPS | -3.66 | -1.26 | -2.00 | -1.79 | -1.44 |
| EPS Diluted | -7.09 | -2.49 | -3.44 | -3.42 | -2.85 |
| Normalized Diluted EPS | -3.66 | -1.26 | -2.00 | -1.79 | -1.44 |
| Average Basic Shares Outstanding | 5.57M | 5.40M | 4.67M | 4.39M | 4.38M |
| Average Diluted Shares Outstanding | 5.57M | 5.40M | 4.67M | 4.39M | 4.38M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |